RemeGen : INSIDE INFORMATION ANNOUNCEMENT - APPROVAL BY THE CSRC OF THE APPLICATION IN RESPECT OF H SHARE FULL CIRCULATION PROGRAMME OF THE COMPANY

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RemeGen Co., Ltd.*

࿲׹͛يႡᖹ€๧ٰ̨΅Ϟࠢʮ̡

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

INSIDE INFORMATION ANNOUNCEMENT

APPROVAL BY THE CSRC OF THE APPLICATION IN RESPECT OF H

SHARE FULL CIRCULATION PROGRAMME OF THE COMPANY

This announcement is made by RemeGen Co., Ltd.* ࿲׹͛يႡᖹ€๧ٰ̨΅Ϟࠢʮ̡(the "Company") pursuant to Rule 13.09(2)(a) of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the "Board") is pleased to announce that on March 25, 2021, the Company received the official approval (the "Approval") from the China Securities Regulatory Commission (the "CSRC") regarding the implementation of the H share full circulation programme of the Company, pursuant to which up to 71,232,362 unlisted shares can be converted into H shares of the Company and their listing thereof on the Stock Exchange (the "Conversion and Listing"). Once converted, the total number of H shares listed and circulated on the Stock Exchange will be up to 189,581,239, which represent approximately 38.7% of total shares outstanding of the Company. The Approval shall be valid for 12 months from March 17, 2021.

The Company will make further announcements on the progress of the Conversion and Listing in compliance with the Listing Rules and other applicable rules. Completion of the Conversion and Listing is subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other onshore and offshore regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

RemeGen Co., Ltd.

Mr. Wang Weidong

Chairman and executive director

Yantai, The People's Republic of China

March 25, 2021

As at the date of this announcement, the Board of the Company comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Ms. Yu Shanshan, Mr. Hao Xianjing and Dr. Lorne Alan Babiuk as the independent non-executive directors.

* For identification purposes only